CEO-Column

Message from CEO

Thank you for visiting the website of Medical Excellence JAPAN (MEJ).

We are living in an era of unprecedented uncertainty and fragmentation.
Yet, even amid such times, through dialogue with numerous countries and medical institutions, I strongly feel that expectations toward Japan – and particularly toward Japanese healthcare – are higher than ever before.

Enduring infectious diseases, cancer, cardiovascular conditions, rare diseases, and the challenges of a super-aged society, to advance medicine in the face of these complex global issues, cross-border collaboration and mutual learning are indispensable.

Japan’s proven medical quality, outstanding clinical capabilities and multidisciplinary team-based care, cutting-edge technologies, and rich experience represent invaluable “assets of knowledge and skill” grounded in international trust. They form the very core of Japan’s global competitiveness – our true killer content.


Recently, the director of a leading medical tourism hospital in Thailand visited Japan. After observing Japanese surgeons at work, he expressed deep admiration, saying, “I would like to send our patients here.” What we in Japan often take for granted is, in fact, highly valued and deeply appreciated around the world. This excellence is not only a national strength but also a sector that should develop into one of Japan’s key industries. MEJ’s mission is to serve as a bridge – adapting Japan’s healthcare to align with each country’s systems and needs and transforming it into value shared by both patients and providers.

Major Initiatives in 2025

Across Asia in particular, demand for Japanese healthcare continues to expand steadily. Expectations from partner countries are becoming increasingly proactive and specific. Harnessing this favorable environment, MEJ’s initiatives are steadily moving forward.

  • China: Based on an MOU with the China Non-Government Medical Institutions Association (CNMIA), MEJ we welcomed approximately 70 physicians and hospital management leaders from private hospitals to Japan. The inaugural Japan-China Medical Cooperation Forum generated a series of concrete collaboration themes between hospitals and companies.
  • India: Full-scale collaboration has begun with companies under the Confederation of Indian Industry (CII). Through market research and business matching, candidate projects for Japan-India cooperative demonstration initiatives are taking shape.
  • Vietnam: Together with 108 Military Central Hospital and ERIA, we are advancing the creation of a Japan-Vietnam Medical Cooperation Center – a hub integrating education, clinical practice, and hospital management as a new Japan-Vietnam model.
  • Thailand: In line with the government’s Medical Hub / Wellness Hub Policy, collaboration with the BDMS Group is taking concrete form, building a new medical model that fuses advanced treatment and wellness.
  • Medical Inbound: The international promotion of Japan International Hospitals (JIH) is being strengthened. A new patient-centered platform to support overseas patient acceptance is under development. It will bring Japanese healthcare even closer to the world.

Healthcare is an infrastructure of hope.
With implementation grounded in the field, MEJ will further evolve its unique platform uniting industry, government, academia, and medicine. Together, we will steadily open a future where Japanese healthcare learns and grows alongside the world.

Connecting every cross-border encounter to a “better tomorrow” for both patients and healthcare professionals – That is our mission.

From Japan’s healthcare, to the world’s future
With this vision in our hearts, we look forward to co-creating the next decisive steps together with you.

Kenji Shibuya Chief Executive Officer, MEJ

Click here for the Chief Executive Officer’s work history

Chief Executive Officer, Medical Excellence JAPAN
Dr. Kenji Shibuya is a renowned expert in the field of global and population health. He currently holds multiple prestigious positions, including Senior Executive Director of Medical Excellence JAPAN, Research Director at the Tokyo Foundation for Policy Research, Managing Director at the Soma COVID Vaccination Medical Center in Soma City, Fukushima, and Venture Partner of Eight Roads Ventures Japan. Previously, Dr. Shibuya served as a Professor and Director of the University Institute for Population Health at King's College London. Before his time at King's, he held the position of Professor and Chair of the Department of Global Health at the University of Tokyo.
Dr. Shibuya possesses a wide range of expertise in various crucial areas of global and population health. His knowledge spans health metrics and evaluation, global burden of disease, health system performance, product and system innovations, public-private partnerships, and R&D strategies. Throughout his career, Dr. Shibuya has been an advisor to both central and local governments.
Notably, he served as a Special Advisor to the Director-General of the World Health Organization (WHO) and was a member of the Scientific Advisory Committee of the Coalition for Epidemic Preparedness Innovations (CEPI), a pandemic vaccine fund that invested in COVID-19 vaccines.
Dr. Shibuya played a pivotal role in shaping the strategic directions of Japanese global health policy. He spearheaded discussions on health system strengthening at the Hokkaido Toyako G8 Summit in 2008 and global health security at the Ise-Shima G7 Summit in 2016.
He completed his medical degree at the University of Tokyo and earned a doctorate of public health in international health economics from Harvard University.


Top
Top